Host of Other Catalysts Beyond Teva's Big Copaxone Decision |
![]() |
![]() |
By M.E.Garza | |
Sunday, 24 June 2012 17:45 | |
![]() A U.S. District Court judge on Friday rejected challenges to the Copaxone patents. This decision covers several patents, the last of which expires on September 1, 2015. The judge rejected Momenta/Sandoz and Mylan/Natco’s claims that the COPAXONE® patents are invalid and unenforceable and found that the purported generic versions of COPAXONE® for which Momenta/Sandoz and Mylan/Natco seek Food and Drug Administration (FDA) approval infringe those patents. This ruling should prevent the FDA from approving, and the defendants from selling their purported generic versions of COPAXONE® in the U.S. until the Orange Book patents expire on May 24, 2014. In an earlier note to clients, analysts Randall Stanicky, CFA and Dana Flanders of Canaccord Genuity stated: "Should TEVA win and gain patent protection into 2015, Street numbers would have to move higher and lifecycle The analysts see a solid outlook beyond the Copaxone decision, stating: "There are a host of catalysts coming up including new CEO (May), GALA data (July) and R&D day (September) that combined with several product catalysts and a solid P&L outlook set the stock up well for H2/2012." "Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'. Add this page to your favorite Social Bookmarking websites ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |